Financière de Tubize SA (TUB.BR)

79.4 €

+0.80 (+1.02%)
Rating:
Recommendation:
-
Symbol TUB.BR
Price 79.4 €
Beta 0.617
Volume Avg. 0.01M
Market Cap 3.531B
Shares () -
52 Week Range 72.6-100.8
1y Target Est -
DCF Unlevered TUB.BR DCF ->
DCF Levered TUB.BR LDCF ->
ROE 9.66% Neutral
ROA 8.69% Neutral
Operating Margin -
Debt / Equity 0.64% Neutral
P/E 9.30 Strong Buy
P/B 1.09 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
Brussels

Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.